Clinical trial NCT06229366: [Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer
Official title: [Ac-225]-PSMA-62 Phase I/II Clinical Trial to Characterize Efficacy, Safety, Tolerability, and Dosimetry in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer (ACCEL)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Oligometastatic Prostate Carcinoma
Hormone Sensitive Prostate Cancer
Keywords: mCRPC
OmHSPC
Prostatic Neoplasms
Genital Neoplasms, Male
Castration Resistant Prostate Cancer
Hormone Sensitive Prostate Cancer
Oligometastatic Prostate Cancer
[225Ac]-PSMA-62
Ac-225-PSMA-62
Actinium
Radioligand Therapy
Radiopharmaceuticals
Urogenital Neoplasm
Lead sponsor: Eli Lilly and Company
Sponsor class: INDUSTRY
First posted: 2024-01-29
Enrollment: 142
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: ACCEL is a multicenter, open label phase Ia/Ib/II study of \[Ac-225\]-PSMA-62 in participants with prostate-specific membrane antigen (PSMA)-positive prostate cancer.

Detailed description: The primary aim of the phase Ia study is to evaluate the safety and tolerability of \[Ac-225\]-PSMA-62 to determine the maximum tolerated dose (MTD). The primary aim of the randomized phase Ib dose optimization is to determine the recommended phase II doses (RP2D) for patients with mCRPC and OmHSPC. The aim of the phase II study for patients with mCRPC is to evaluate the efficacy of \[Ac-225\]-PSMA-62.

Eligibility criteria: Inclusion Criteria:

1. Histological, pathological, and/or cytological confirmation of adenocarcinoma of the prostate
2. ECOG performance status 0 to 1
3. Criteria specific for patients with mCRPC:

   1. Previously received an androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy (unless ineligible or refused taxane). Received a maximum of 3 prior systemic therapy regimens in the mCRPC setting
   2. Progressive mCRPC at the time of consent based on at least 1 of the following criteria being met in the context of castrate levels of testosterone:

      * PSA progression defined as rising PSA values at a minimum of 1-week intervals, with the last result being at least 1.0 ng/mL
      * Soft-tissue progression defined as an increase ≥20% in the sum of the diameter (SOD) (short axis for nodal lesions and long axis for non-nodal lesions) of all target lesions based on the smallest SOD since treatment started or the appearance of one or more new lesions
      * Progression of bone disease defined as the appearance of two or more new lesions by bone scan
   3. At least one PSMA-PET positive lesion for prostate cancer
   4. Castrate circulating testosterone levels (\<1.74 nmol/L or \<50 ng/dL)
4. Criteria specific for patients with OmHSPC:

   1. PSA recurrence after radical prostatectomy (RP) or definitive radiation therapy (RT), with or without adjuvant/salvage local therapy (radiation or surgery), with or without (neo)adjuvant ADT

      * PSA ≥ 0.2ng/mL for patients with prior RP +/- RT, or
      * PSA of ≥ 2 ng/mL above nadir for patients with only prior RT
   2. 1- 5 PSMA-PET positive lesions identified outside the prostate bed or remaining gland.

Exclusion Criteria:

1. Patient has received any other investigational therapeutic agents within 4 weeks or 5 half-lives (whichever is shorter) of starting the study treatment
2. Evidence of ongoing and untreated urinary tract obstruction
3. Existing Grade 1 dry mouth (xerostomia) or symptomatic Grade 1 dry eye (xerophthalmia) for any reason
4. Patient has any concurrent severe and/or uncontrolled medical conditions that could increase the patient's risk for toxicity while on the study or that could confound discrimination between disease- and study treatment-related toxicities
5. Criteria specific for patients with mCRPC:

   1. Patient has received any PSMA-directed radioligand therapy (e.g., Lu-177-PSMA, Lu-177-PNT2002, Ac-225-J591)
   2. Patient has received any therapeutic systemic radionuclides (e.g., radium-223, rhenium-186, strontium-89), or non-PSMA-directed therapeutic radioligands (e.g., Lu-177-Dotatate) within 5 half-lives of starting the study treatment
6. Criteria specific for patients with OmHSPC:

   1. Patient has received any systemic anti-cancer therapy for prostate cancer with the exception of (neo)adjuvant ADT for management of localized disease
   2. Presence of any liver metastases
   3. Known presence of central nervous system metastases

Primary outcomes:
measure: Maximum tolerated dose (MTD)
timeFrame: From first dose of study drug through end of DLT period (4 weeks)
measure: Safety, tolerability, and Recommended Phase II Dose (RP2D)
timeFrame: From first dose of study drug through end of treatment (~16 - 24 weeks)
measure: Safety and tolerability
timeFrame: From first dose of study drug through end of treatment (~16 - 24 weeks)
Secondary outcomes:
measure: The incidence of treatment emergent adverse events as assessed per CTCAE v5.0
timeFrame: From first dose of study drug through end of study (~5 years)
measure: Time to initiation of any life-long ADT, or other systemic hormonal therapies for prostate cancer
timeFrame: From first dose of study drug through end of study (~5 years)
measure: Absorbed dose estimates (Gy) in normal organs
timeFrame: From first dose of study drug through end of treatment (~16 - 24 weeks)
measure: The proportion of patients with a PSA change from baseline
timeFrame: From first dose of study drug through efficacy follow-up period (up to approximately 3 years)
measure: Objective Response Rate (ORR)
timeFrame: From first dose of study drug until disease progression (up to approximately 3 years)
measure: Radiographic progression free survival (rPFS)
timeFrame: From first dose of study drug until disease progression (up to approximately 3 years)
measure: Patient Reported Outcome (PRO) - Pain
timeFrame: From first dose of study drug until disease progression (up to approximately 3 years)
measure: Patient Reported Outcome (PRO) - Impact of treatment toxicity
timeFrame: From first dose of study drug until disease progression (up to approximately 3 years)
Other outcomes:
Locations:
city: Vancouver
country: Canada
facility: BC Cancer Vancouver
state: British Columbia
city: Hamilton
country: Canada
facility: Juravinski
state: Ontario
city: Toronto
country: Canada
facility: Princess Margaret Cancer Centre
state: Ontario
city: Montreal
country: Canada
facility: Jewish General Hospital
state: Quebec
city: Montreal
country: Canada
facility: McGill University
state: Quebec
city: Saguenay
country: Canada
facility: Hopital De Chicoutimi
state: Quebec
city: Quebec
country: Canada
facility: Centre Hospitalier Universite de QUEBEC
Study officials:
affiliation: Eli Lilly and Company
name: Richard Cioci
role: STUDY_DIRECTOR
References: